U.S. Court of Appeals rules that the PTAB applied the wrong legal standard for conception in the CRISPR-Cas9 interference dispute with the Broad Institute. Decision…
Making CRISPR more accessible for scientific innovation At ERS Genomics, we make CRISPR/Cas9 accessible to innovators. By licensing the foundational IP co-owned by Professor…
License agreement provides Jumpcode Genomics access to CRISPR gene editing technology to enhance next-generation sequencing capabilities Dublin, Ireland, and San Diego, CA, 27 March,…
European Patent Office grants new CRISPR/Cas9 patent (EP 4 289 948) to CVC, with broad claims covering guide RNAs and their combination with Cas9. Patent…
The new Express License service removes barriers to accessing this transformative gene editing technology for startups. An Express License provides fast, simple and affordable…
ERS Genomics stands as the global leader in CRISPR/Cas9 licensing, uniquely positioned at the intersection of cutting-edge science, commercial accessibility, and responsible innovation. Our…
ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement License agreement provides Université de Montréal access to CRISPR gene editing technology for use across…